Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $7.7 million.

  • Beam Therapeutics' Cash from Financing Activities rose 32.73% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $479.6 million, marking a year-over-year increase of 1161.96%. This contributed to the annual value of $7.7 million for FY2024, which is 97.20% down from last year.
  • According to the latest figures from FY2024, Beam Therapeutics' Cash from Financing Activities is $7.7 million, which was down 97.20% from $276.4 million recorded in FY2023.
  • Over the past 5 years, Beam Therapeutics' Cash from Financing Activities peaked at $756.1 million during FY2021, and registered a low of $7.7 million during FY2024.
  • Its 3-year average for Cash from Financing Activities is $131.9 million, with a median of $111.6 million in 2022.
  • As far as peak fluctuations go, Beam Therapeutics' Cash from Financing Activities soared by 680.84% in 2020, and later tumbled by 97.20% in 2024.
  • Yearly analysis of 5 years shows Beam Therapeutics' Cash from Financing Activities stood at $322.3 million in 2020, then surged by 134.59% to $756.1 million in 2021, then slumped by 85.24% to $111.6 million in 2022, then surged by 147.74% to $276.4 million in 2023, then plummeted by 97.20% to $7.7 million in 2024.